lestaurtinib

DRUG4 trials

Sponsors

New Approaches to Neuroblastoma Therapy Consortium, Children's Oncology Group, Cephalon

Conditions

Acute Lymphoblastic LeukemiaAcute Undifferentiated LeukemiaChildhood T Acute Lymphoblastic LeukemiaEssential ThrombocytosisLeukemiaNeuroblastomaPolycythemia Vera

Phase 1

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

CompletedNCT00084422

New Approaches to Neuroblastoma Therapy ConsortiumNeuroblastoma

Start: 2003-08-31End: 2011-02-28Updated: 2023-04-10

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

CompletedNCT00469859

Children's Oncology GroupLeukemia

Start: 2007-06-30End: 2010-03-31Updated: 2017-03-15

Phase 2

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

CompletedNCT00586651

CephalonEssential Thrombocytosis, Polycythemia Vera

Start: 2007-12-31End: 2010-09-30Updated: 2015-10-08

Phase 3

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

CompletedNCT00557193

Children's Oncology GroupAcute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia

Start: 2008-01-15End: 2024-06-30Updated: 2024-07-15

Related Papers

Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials.

2023-02-0152 citations

Open‐label study of oral <scp>CEP</scp>‐701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with <i><scp>JAK</scp>2‐</i>V617F mutation

British Journal of Haematology2013-10-2827 citations